Overview

Update
Status
Acquired by on November 24, 2014
IPO / Stock
Went Public on Apr 12, 2002 / NASDAQ:RNA
Headquarters:
Leiden
Description:
Prosensa provides RNA-based therapeutics for the treatment of genetic disorders, infections and cancers.
Categories:
Therapeutics, Health Care, Biotechnology, Medical
Website:
http://www.prosensa.eu
Social:

Company Details

Update

Prosensa is a biotech company also known as Ribpharm Inc dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics.

During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology.

Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.

Funding Rounds (4) - $73.27M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jul, 2014$200k / Grant1
Jan, 2012€23M / Venture7
Dec, 2008€18M / Series B2
Feb, 2007$18M / Series A2

Current Team (12)

Update

Offices/Locations (2)

Update
  • Office

    Leiden,

    NLD

  • Headquarters

    J.H. Oortweg 21 Leiden

    Leiden, 2333

    NLD

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos